Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)

• Status: Completed
• Trial end date: 2003-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the safety and efficacy of ertapenem versus ceftriaxone in pediatric patients with urinary tract infections, skin infections, or community-acquired pneumonia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Ceftriaxone; Ertapenem

Criteria

Inclusion Criteria:

• Patients with UTI must have white blood cells and bacteria in the urine with bladder catheterization or urologic abnormality, kidney infection or both

• Patients with SSTI must have a recent infection

• Patients with CAP must have a chest x-ray indicating bacterial pneumonia and a fever

Exclusion Criteria:

• Patients with complete urinary tract blockage or kidney abscess

• Patients with infected burn wounds, bone infection, or bacterial arthritis

• Patients on mechanical ventilation or those with cystic fibrosis, chronic lung disease or puss in the space between the chest wall and lung